Related Experiment Video
Updated: Aug 18, 2025

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
Published on: January 20, 2019
Characterization of the Second Apoptosis Inhibitor Encoded by Guinea Pig Cytomegalovirus
Keisuke Satoh1, Keita Takahashi1, Kazuma Noguchi1
1Microbiology & Immunology, Gifu Pharmaceutical University, Gifu, Japan.
Abstract:
Despite the usefulness of guinea pig cytomegalovirus (GPCMV) for studies on congenital CMV infection, its viral mechanisms for the evasion of host defense strategies have not been fully elucidated. We reported previously that GPCMV gp38.1 functions as a viral mitochondria-localized inhibitor of apoptosis-like function, and its weak activity suggested the presence of an additional inhibitory molecule(s). Here, we identified gp38.3-2, a 42-amino-acid (aa) reading frame embedded within the gp38.3 gene that encodes a positional homolog of murine CMV (MCMV) m41. Characterization of gp38.3-2 resulted in the following findings: (i) the aa sequence of gp38.3-2 shows some similarity to that of MCMV m41.1, a viral inhibitor of oligomerization of a member of Bcl-2 family protein BAK, but there is no correspondence in their predicted secondary structures; (ii) gp38.3-2, but not gp38.3, showed inhibitory activities against staurosporine-induced apoptosis; (iii) three-dimensional protein complex prediction suggests that the N-terminal α-helix of gp38.3-2 interacts with residues in the BH3 and BH1 motifs of BAK, and analysis of gp38.3-2 and BAK mutants supported this model; (iv) guinea pig fibroblast cells infected with gp38.3-2-deficient GPCMV strain Δ38.3-2 died earlier than cells infected with rescued strain r38.3-2, resulting in lower yields of Δ38.3-2; (v) Δ38.3-2 exhibited a partial but significant decrease in monocyte and macrophage infection in comparison with r38.3-2; and, however, (vi) little difference in the viral infection of guinea pigs was observed between these two strains. Therefore, we hypothesize that gp38.3-2 contributes little to the evasion of host defense mechanisms under the experimental conditions used. IMPORTANCE Although GPCMV provides a useful animal model for studies on the pathogenesis of congenital CMV infection and the development of CMV vaccine strategies, our understanding of the viral mechanisms by which it evades apoptosis of infected cells has been limited in comparison with those of murine and human CMVs. Here, we report a second GPCMV apoptosis inhibitor (42 amino acids in length) that interacts with BAK, a Bcl-2 family proapoptotic protein. Three-dimensional structural prediction indicated a unique BAK recognition by gp38.3-2 via the BH3 and BH1 motif sequences. Our findings suggest the potential development of BH3 mimetics that can regulate inhibition or induction of apoptosis based on short ~40-amino-acid peptide molecules as with GPCMV.
Insights
Guinea pig cytomegalovirus (GPCMV) has a second apoptosis inhibitor, gp38.3-2, which interacts with the proapoptotic protein BAK. This finding advances understanding of viral evasion mechanisms and potential therapeutic strategies.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Guinea pig cytomegalovirus (GPCMV) is a model for congenital CMV infection.
- Viral mechanisms for evading host defenses, particularly apoptosis, are not fully understood.
- Previous work identified GPCMV gp38.1 as a weak inhibitor of apoptosis.
Purpose of the Study:
- To identify and characterize additional GPCMV proteins involved in apoptosis evasion.
- To investigate the interaction of GPCMV gp38.3-2 with host cell apoptosis pathways.
- To assess the in vivo and in vitro roles of gp38.3-2 in viral pathogenesis.
Main Methods:
- Sequence analysis and comparison with murine CMV (MCMV) m41.
- Apoptosis inhibition assays using staurosporine.
- Three-dimensional protein complex prediction and mutant analysis.
- Infection of guinea pig fibroblast cells and assessment of viral yields.
- Analysis of monocyte, macrophage, and whole guinea pig infection.
Main Results:
- gp38.3-2, a 42-amino acid protein, showed similarity to MCMV m41.1.
- gp38.3-2 inhibited staurosporine-induced apoptosis by interacting with BAK's BH3 and BH1 motifs.
- GPCMV lacking gp38.3-2 (Δ38.3-2) showed earlier cell death and reduced viral yields.
- Δ38.3-2 exhibited decreased infection of monocytes and macrophages.
- No significant difference in infection was observed in whole guinea pigs.
Conclusions:
- gp38.3-2 is a novel GPCMV apoptosis inhibitor that targets BAK.
- The gp38.3-2 interaction with BAK is structurally unique.
- gp38.3-2 plays a role in cell apoptosis and monocyte/macrophage infection in vitro.
- gp38.3-2 appears to contribute minimally to host defense evasion in vivo under tested conditions.
- Findings suggest potential for developing BH3 mimetic therapeutics based on short peptides.

